<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566316</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TAR-301</org_study_id>
    <nct_id>NCT03566316</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia</brief_title>
  <official_title>Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy&#xD;
      and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive&#xD;
      Patients with Hyperlipidemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2015</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 16, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of change in LDL-Cholesterol</measure>
    <time_frame>From baseline at week 8</time_frame>
    <description>Telmisartan/Amlodipine/Rosuvastatin versus Telmisartan/Amlodipine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change of sitting systolic blood pressure</measure>
    <time_frame>From baseline at week 8</time_frame>
    <description>Telmisartan/Amlodipine/Rosuvastatin versus Telmisartan/Rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in LDL-Cholesterol</measure>
    <time_frame>From baseline at week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change in HDL-Cholesterol, total Cholesterol, Triglyceride, Apolipoprotein B</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of HDL-Cholesterol/LDL-Cholesterol ratio</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of total cholesterol/HDL-Cholesterol ratio</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching treatment goals according to National Cholesterol Education Program-Adults Treatment Panel III Guideline</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of sitting diastolic blood pressure</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching treatment goals according to Joint National Committee VIII Guideline</measure>
    <time_frame>From baseline at week 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Hypertension With Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine+Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan +Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine</intervention_name>
    <arm_group_label>Telmisartan/Amlodipine</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine+Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Telmisartan +Rosuvastatin</arm_group_label>
    <arm_group_label>Telmisartan/Amlodipine+Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan +Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 19 years old or above&#xD;
&#xD;
          2. Patients who confirmed essential hypertension with Hyperlipidemia or use of drugs at&#xD;
             Visit 1 (sit systolic blood pressure ≥ 140mmHg, LDL-Cholesterol ≥ 100mg/dL)&#xD;
&#xD;
          3. Patients who can stop the treatment of anti-hypertensive/anti-hyperlipidemic drugs in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          4. Test results showing the following values at screening time (Visit 2) : sit systolic&#xD;
             blood pressure &gt;140mmHg&#xD;
&#xD;
          5. Test results showing the following values at screening time (Visit 2) : 100&lt;&#xD;
             LDL-Cholesterol &lt;250&#xD;
&#xD;
          6. Patients who agreed to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe hypertension patients(systolic blood pressure ≥ 180 mm Hg or diastolic blood&#xD;
             pressure ≥ 110 mm Hg)&#xD;
&#xD;
             -The change of mean sit systolic blood pressure ≥ 20 mmHg or sit diastolic blood&#xD;
             pressure ≥ 10 mmHg on target arm between 1st and 2nd measurement&#xD;
&#xD;
          2. LDL-Cholesterol &gt; 250 mg/dL or triacylglycerol ≥ 400 mg/dL at screening time(Visit 1)&#xD;
&#xD;
          3. Patients with postural hypotension who have sign and symptom&#xD;
&#xD;
          4. Patients with secondary blood pressure(for example,aortic coarctation,&#xD;
             hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma,&#xD;
             Polycystic Kidney Diseases)&#xD;
&#xD;
          5. Patients with congestive heart failure(New York Heart Association class III~IV)&#xD;
&#xD;
          6. Patients with history of acute coronary syndrome or underwent revascularization&#xD;
             (percutaneous transluminal coronary angioplasty or Coronary Artery Bypass Graft&#xD;
             surgery ) within 6 months&#xD;
&#xD;
          7. Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter&#xD;
             or clinically significant arrhythmia&#xD;
&#xD;
          8. Causes of hemodynamic disorder or structural heart defect such as valvular heart&#xD;
             disease&#xD;
&#xD;
          9. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral&#xD;
             hemorrhage within 6 months prior to study entry&#xD;
&#xD;
         10. Patients with primary aldosteronism&#xD;
&#xD;
         11. Patients with severe ocular disorders&#xD;
&#xD;
         12. Patients with autoimmune disease&#xD;
&#xD;
         13. Patients with any chronic inflammation disease needed to chronic inflammation therapy&#xD;
&#xD;
         14. Patients with uncontrolled diabetes Mellitus with HbA1c &gt; 9% or thyroid diseases(TSH ≥&#xD;
             1.5 X ULN)&#xD;
&#xD;
         15. Patients who have a history of myopathy or rhabdomyolysis&#xD;
&#xD;
         16. Patients who have 3 times of upper limit of normal range of muscle enzyme (creatinine&#xD;
             kinase, CK)&#xD;
&#xD;
         17. History of malignant tumor including leukemia, lymphoma within 5 years&#xD;
&#xD;
         18. Patients with one kidney&#xD;
&#xD;
         19. Patients with biliary obstructive disorder&#xD;
&#xD;
         20. Patients with clinically significant electrolyte disturbance&#xD;
&#xD;
         21. Continued serum potassium concentration abnormal status (&lt;3.5mEq/L or &gt;5.5mEq/L)&#xD;
&#xD;
         22. Patients with sodium ion or body fluid is depleted and not able to correct&#xD;
&#xD;
         23. Patients with clinically significant liver/renal disease&#xD;
&#xD;
         24. Patients with digestive diseases that may affect the absorption or history in&#xD;
             gastrointestinal surgery&#xD;
&#xD;
         25. Patients who are dependent on drugs or alcohol&#xD;
&#xD;
         26. Pregnancy, breast-feeding, or child-bearing potential Patients&#xD;
&#xD;
         27. Patients with hypersensitivity to telmisartan or other angiotensin II receptor&#xD;
             blockers&#xD;
&#xD;
         28. Patients with hypersensitivity to Amlodipine or other dihydropyridine drugs&#xD;
&#xD;
         29. Patients with history of Myotoxicity to other 3-hydroxy-methyl glutaryl-coenzyme A&#xD;
             reductase inhibitor or fibrate&#xD;
&#xD;
         30. Patients who are unable to stop taking prohibited drugs to combination during study&#xD;
             period&#xD;
&#xD;
         31. Patients who have galactose intolerance&#xD;
&#xD;
         32. Patients taking other clinical trial drugs within 30 days from the time of visit for&#xD;
             screening&#xD;
&#xD;
         33. Patients that is not eligible to participate at the discretion of study investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>June 20, 2018</last_update_submitted>
  <last_update_submitted_qc>June 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Telmisartan amlodipine combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

